Fallopian tube cancer

 Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Retrieved on: 
Thursday, March 7, 2024
Research, Women, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Oncology, Cancer, Woman, Omics, Uterine serous carcinoma, Female, EOC, Risk, Safety, Biomarker, Prognosis, Endometrial cancer, DDR, USC, Patient, Fibroadenoma, Infection, Diagnosis, WEE1, Lymph, Fallopian tube cancer

The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.

Key Points: 
  • The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.
  • Two out of the three expansion arms of the study will be using biomarkers to pre-select patients with different solid tumors while the third arm will be treating patients with recurrent serous endometrial carcinoma.
  • Maximizing efficacy, while preserving safety are key elements that Debiopharm is eager to assess throughout the clinical development of Debio 0123.
  • With the successful realization of these requirements, Debio 0123 could become the first choice WEE1 inhibitor.

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

Retrieved on: 
Wednesday, January 31, 2024
Epithelium, Ovarian cancer, Survival, Cancer, BNTX, Fast Track, Peritonitis, Patient, Ovary, Fast track (FDA), FDA, BioNTech, Food, ADC, Fallopian tube cancer, Vaccine, Hope, Glomus tumor

BNT325/DB-1305 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the trophoblast cell-surface antigen 2 (“TROP2”), a protein which is overexpressed on a range of tumor types.

Key Points: 
  • BNT325/DB-1305 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the trophoblast cell-surface antigen 2 (“TROP2”), a protein which is overexpressed on a range of tumor types.
  • The candidate is currently being evaluated in an ongoing Phase 1/2 study ( NCT05438329 ) in patients with TROP2-expressing advanced solid tumors.
  • Platinum-based chemotherapy is the backbone of treatment for ovarian epithelial cancer and related subtypes that form in the epithelial tissue.
  • “Recent studies have indicated the role of TROP2 in aggressive tumor growth and progression in patients with chemotherapy-resistant ovarian tumors.

Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023

Retrieved on: 
Wednesday, October 11, 2023
MSD, Congress, Senior, Hepatocellular carcinoma, Abstract, Pembrolizumab, Trial of the century, Bristol Myers Squibb, Merck & Co., Safety, Lung cancer, FR, Endometrial cancer, LEAP, Cancer, Fallopian tube cancer, Patient, FDA, ESMO, Oncology, Ovarian cancer, Meta-analysis, Merck, Research, Science, Lenvatinib, European Society for Medical Oncology, ADC, Pharmaceutical industry, Eisai

We also look forward to sharing data for lenvatinib and from our pipeline, as well as engaging in critical scientific exchange with the community in service of moving oncology research forward."

Key Points: 
  • We also look forward to sharing data for lenvatinib and from our pipeline, as well as engaging in critical scientific exchange with the community in service of moving oncology research forward."
  • A network meta-analysis of lenvatinib versus key comparators as first-line treatment for patients with unresectable hepatocellular carcinoma will also be presented during a poster session (Presentation: #1007P).
  • These abstracts will be made available via the ESMO website on Monday, October 16, 2023, at 12:05 AM CEST.
  • In June 2021, Eisai and Bristol Myers Squibb entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of FZEC.

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023

Retrieved on: 
Wednesday, May 24, 2023
MSD, CREB-binding protein, Apoptosis, Carcinoma, Abstract, Senior, CBP, FR, Pembrolizumab, Cancer, Fallopian tube cancer, Bristol Myers Squibb, Research, Lung cancer, Trial of the century, ASCO, LEAP, Endometrial cancer, American Society of Clinical Oncology, Patient, Physician, Sorafenib, Oncology nursing, Annual general meeting, ADC, Merck, Poster, Merck & Co., FDA, Survival analysis, Ovarian cancer, Society, HCC, Safety, Nivolumab, Pharmaceutical industry, Eisai

Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.

Key Points: 
  • Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.
  • A Phase 1/2 clinical study of BB-1701 in the U.S. and China for HER2-expressing solid tumors is currently underway.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai and Merck are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in various tumor types across more than multiple clinical trials.

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, CT, Senior, Fallopian tube cancer, Overalls, Survival, Cancer, Fallopian tube, Gynecologic Oncology (journal), Peritonitis, ImmunoGen, Mirvetuximab soravtansine, IMGN, Associate, ASCO, Bevacizumab, American Society of Clinical Oncology, MD, Patient, University, Randomness, Clinical research, University of Oklahoma, Annual general meeting, Spacecraft, GOG, Society, Safety, Birth control, Maintenance

"We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.

Key Points: 
  • "We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.
  • "Having demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to investigator's choice of single-agent chemotherapy, I believe ELAHERE has the potential to be practice changing in FRα-positive, platinum-resistant ovarian cancer."
  • Title: Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study: Initial Report of Mirvetuximab Soravtansine vs.
  • ImmunoGen will present two additional trial-in-progress posters at ASCO.

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Partnership, Therapy, American Society of Clinical Oncology, Fallopian tube cancer, Medication, ASCO, Malignancy, Patient, SAN, Roche, Cancer, Poster, Foundation Medicine, Ovarian cancer, Society, Pharmaceutical industry, Medical imaging, Cyclin

NEW YORK and SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, announced today that it will present positive clinical data from its Phase 1b trial investigating azenosertib in combination with chemotherapy in patients with advanced platinum-resistant ovarian cancer in a poster at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, June 2-6, 2023. Azenosertib is the Company's potentially first-in-class Wee1 inhibitor currently being investigated in multiple clinical trials as a monotherapy and in combination.

Key Points: 
  • Azenosertib is the Company's potentially first-in-class Wee1 inhibitor currently being investigated in multiple clinical trials as a monotherapy and in combination.
  • These encouraging clinical data, together with the preclinical data we recently presented at the 2023 AACR Annual Meeting, provide clear support for the use of Cyclin E1 expression as a predictive marker to identify patients who may significantly benefit from treatment with azenosertib,” said Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis.
  • The current Foundation Medicine partnership involves global prospective genomic profiling for potential patient enrollment in Zentalis’ Phase 2 clinical trial of azenosertib in Cyclin E1 driven high-grade serous ovarian cancer.
  • The companies are also exploring opportunities to develop Foundation Medicine’s tissue-based next generation sequencing assay as a companion diagnostic for azenosertib.

Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

Retrieved on: 
Wednesday, April 12, 2023
Maintenance, Communication, ADP, Fallopian tube cancer, FLAMES, PFS, Trial of the century, Death, SSE, HKEX, Patient, IMPACT, Gynaecology, BRCA, Ovarian cancer, Therapy, PARP, Cancer, III, Female, Pharmaceutical industry, Obstetrics

The Independent Data Monitoring Committee (the “IDMC”) concluded that the primary endpoint had met the pre-defined efficacy boundary.

Key Points: 
  • The Independent Data Monitoring Committee (the “IDMC”) concluded that the primary endpoint had met the pre-defined efficacy boundary.
  • Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences, commented on the positive results of the FLAMES study.
  • Although primary platinum-based chemotherapy can help alleviate ovarian cancer, most patients inevitably experience cancer relapse.
  • In particular, PARP inhibitor maintenance treatment can extend the response time following first-line platinum-based chemotherapy and delay cancer relapse.

IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer

Retrieved on: 
Monday, February 27, 2023
Clinical trial, Safety, Immunotherapy, Monroe Dunaway Anderson, Patient, University, Koch Institute for Integrative Cancer Research, Reproductive medicine, Ovarian cancer, Bevacizumab, A Second Look (1969 TV series), Fallopian tube cancer, Research, Cancer, MRD, David H. Koch Theater, Progression-free survival, Gynecologic Oncology (journal), MD Anderson Cancer Center, Effect, SLL, PFS, Woman, Clinician Administered PTSD Scale, Therapy, Pharmaceutical industry

LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, and Break Through Cancer, a public foundation dedicated to empowering outstanding researchers and clinicians to both intercept and find cures for some of the most difficult-to-treat cancers, announces the commencement of patient enrollment in a collaboration to evaluate IMUNON’s IMNN-001 (formerly GEN-1) in combination with bevacizumab in patients with advanced ovarian cancer. The trial is now active at the University of Texas MD Anderson Cancer Center. IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).

Key Points: 
  • The trial is now active at the University of Texas MD Anderson Cancer Center.
  • IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).
  • Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy vs. chemotherapy plus IMNN-001.
  • The majority of patients with ovarian cancer are diagnosed with Stage III/IV disease and face low cure rates of 15% or less.

Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference

Retrieved on: 
Monday, February 27, 2023
Medicine, Therapy, Patient, Ovarian cancer, Webcast, Fallopian tube cancer, Conference, ACRV, Cancer, Event, Neoplasm, Platinum, Pharmaceutical industry

ET at the Cowen 43rd Annual Health Care Conference in Boston.

Key Points: 
  • ET at the Cowen 43rd Annual Health Care Conference in Boston.
  • To access the live webcast of this panel, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations .
  • A replay of the webcast will be available via the same link for 90 days following the panel.
  • Ovarian cancer patients must have received at least 1, but can have had up to 6, prior lines of systemic therapy.

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, ARC, Autoimmune disease, Safety, ImmunoGen, Cancer, CD47, Patient, CD40, Fallopian tube cancer, Mirvetuximab soravtansine, Lutheran Student Fellowship, DRS, Growth, Therapy, AML, PS2, Macrophage, TP53, Completeness, CSO, Neoplasm, Pharmacokinetics, Pharmaceutical industry, Azacitidine

“During the fourth quarter of 2022, we continued to focus on clinical execution to position ourselves for key clinical data readouts for SL-172154 in 2023.

Key Points: 
  • “During the fourth quarter of 2022, we continued to focus on clinical execution to position ourselves for key clinical data readouts for SL-172154 in 2023.
  • We look forward to benefiting from the expertise of these scientific program leaders as we continue our momentum in 2023.
  • Dr. Fromm joined Shattuck Labs in 2017 and is one of its scientific co-founders.
  • This increase was primarily driven by a litigation settlement of $1.4 million and increases in personnel-related and other operating costs.